Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2003 01:31 ET | Source: Active Biotech

Positive results confirmed in final report for Active Biotech's TTS cancer product

The primary endpoint was defined as the number of responders to treatment. After 2 and 4 months of TTS CD2 treatment, 68% and 40% of the patients showed stable disease (SD), respectively. Median time...
December 17, 2003 01:30 ET | Source: Active Biotech

Positiva resultat konfirmerade i slutrapport för Active Biotechs cancerprodukt TTS

Det primära målet för studien var definierat som antalet patienter som svarar på behandling. Efter 2 respektive 4 månaders behandling med TTS CD2, uppvisade 68 respektive 40% av patienterna en...
December 08, 2003 11:06 ET | Source: Active Biotech

Decision by Extraordinary General Meeting of Active Biotech AB (publ)

The principal conditions for stock options are as follows: Stock options of series 1 will be allotted in December 2003, granting the opportunity for employees to acquire a maximum of 330,000...
December 08, 2003 10:51 ET | Source: Active Biotech

Beslut från extra bolagsstämma Active Biotech AB (publ)

De huvudsakliga villkoren för personaloptionerna är som följer: Personaloptioner av serie 1 tilldelas i december 2003 och ger de anställda möjlighet att förvärva högst 330.000 aktier under perioden...
November 10, 2003 03:09 ET | Source: Active Biotech

Invitation to Extraordinary General Meeting of Shareholders

Notice of Extraordinary General Meeting of the Shareholders of Active Biotech AB (publ) The shareholders of Active Biotech AB (publ) are hereby invited to attend an Extraordinary General...
November 10, 2003 03:03 ET | Source: Active Biotech

Kallelse till extra bolagsstämma

Kallelsen, som införs idag i Sydsvenskan, Dagens Industri och Post- och Inrikes Tidningar, bifogas. Lund den 10 november 2003 ACTIVE BIOTECH AB (PUBL)STYRELSEN Active Biotech AB är ett...
November 06, 2003 02:00 ET | Source: Active Biotech

Active Biotech Interim Report January - September 2003

For release content, please refer to the attachment....
November 06, 2003 01:30 ET | Source: Active Biotech

Active Biotech Delårsrapport januari - september 2003

For release content, please refer to the attachment....
October 27, 2003 02:01 ET | Source: Active Biotech

Positive preclinical results for Active Biotech's project 57-57 for the treatment of SLE

Oral treatment with doses of 2 or 12 mg/kg of ABR-215757 per day resulted in a statistically significant decrease of kidney inflammation, measured as protein level and blood in the urine, compared to...
October 27, 2003 02:00 ET | Source: Active Biotech

Positiva prekliniska resultat för Active Biotechs projekt 57-57 för behandling av SLE

Data visar att oral behandling med 2 resp. 12 mg/kg/dag av ABR-215757 ger en statistiskt signifikant minskning av njurinflammation mätt som protein och blod i urinen, jämfört med kontrollgruppen. Som...